Dianthus Therapeutics, Inc.
DNTHNASDAQHealthcare● Active
$83.92
+$2.70(+3.32%)
Market Cap$3.5B
P/E Ratio—
52W High$96.5
52W Low$16.64
Dianthus Therapeutics, Inc. (DNTH) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DNTH · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($162.34M) | ($84.97M) | ($43.55M) | ($28.48M) | ($71.14M) |
| Depreciation & Amort. | $0.43M | $0.41M | $0.35M | $0.15M | $2.02M |
| Stock-Based Comp. | $22.79M | $12.89M | $2.90M | $1.52M | $0.00M |
| Change in Working Capital | $16.73M | ($0.35M) | $4.86M | ($1.65M) | ($1.53M) |
| Net Cash from Operations | ($129.06M) | ($78.18M) | ($36.86M) | ($29.07M) | ($59.53M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.21M) | ($0.10M) | ($0.11M) | ($0.14M) | ($1.26M) |
| Purchases of Investments | ($435.01M) | ($413.71M) | ($57.42M) | ($61.68M) | ($45.31M) |
| Sales of Investments | $312.39M | $127.00M | $77.78M | $2.00M | $90.00M |
| Net Cash from Investing | ($122.83M) | ($286.81M) | $20.25M | ($59.82M) | $43.43M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $280.13M | $255.62M | $133.57M | $96.68M | $89.60M |
| Free Cash Flow | |||||
| Free Cash Flow | ($129.27M) | ($78.28M) | ($36.97M) | ($29.21M) | ($60.80M) |
| FCF Margin %(computed) | — | — | — | -455.18% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Dianthus Therapeutics, Inc. data
About Dianthus Therapeutics, Inc. (DNTH) Cash Flow Statement
Dianthus Therapeutics, Inc. generated operating cash flow of ($0.13B) and free cash flow of ($0.13B) for 2025 — a FCF margin of -6349.36%. Capital expenditure was ($0.00B).
Frequently asked questions
DNTH · 4 questionsDianthus Therapeutics, Inc. generated free cash flow of ($0.13B) for 2025, down 65.1% year-over-year.
DNTH free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10